PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
16.52%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
16.61%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
17.14%
Positive EPS growth while GNPX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
17.14%
Positive diluted EPS growth while GNPX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while GNPX stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
FCF growth 1.25-1.5x GNPX's 8.87%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
90.48%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
83.42%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-2587.91%
Negative 10Y net income/share CAGR while GNPX is at 10.09%. Joel Greenblatt sees a major red flag in long-term profit erosion.
90.30%
5Y net income/share CAGR above 1.5x GNPX's 10.09%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
86.48%
Positive short-term CAGR while GNPX is negative. John Neff would see a clear advantage in near-term profit trajectory.
1551.35%
10Y equity/share CAGR above 1.5x GNPX's 473.92%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-71.69%
Negative 5Y equity/share growth while GNPX is at 473.92%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-47.82%
Negative 3Y equity/share growth while GNPX is at 31073.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth well under 50% of GNPX's 62.71%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
15.36%
Under 50% of GNPX's 42.03%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-14.09%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-7.82%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-4.34%
We cut SG&A while GNPX invests at 48.62%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.